Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter

Carcinogenesis

Volumn 29, Issue 9, 2008, Pages 1816-1824

  Nian, Hui ^a   Delage, Barbara ^a   Pinto, John T ^a   Dashwood, Roderick H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLMERCAPTAN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ORGANOSULFUR DERIVATIVE; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HT29; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENHANCER REGION; GARLIC; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MODEL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ACETYLATION; ALLYL COMPOUNDS; BINDING, COMPETITIVE; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLOW CYTOMETRY; GARLIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HT29 CELLS; HUMANS; IMMUNOBLOTTING; MODELS, MOLECULAR; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 51849103354     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn165     Document Type: Article

References (70)

1. Kondo,Y. et al. (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev., 23, 29-39.
2. Hellebrekers,D.M. et al. (2007) Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res., 67, 4138-4148.
3. Taniguchi,H. et al. (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene, 24, 7946-7952.
4. Wade,P.A. (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin. Hum. Mol. Genet., 10, 693-698.
5. McLaughlin,F. et al. (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol., 68, 1139-1144.
6. Mitsiades,C.S. et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc. Natl Acad. Sci. USA, 101, 540-545.
7. Mitic,T. et al. (2005) Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor - a pilot study. Toxicol. Pathol., 33, 792-799.
8. Butler,L.M. et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA, 99 11700-11705.
9. Glaser,K.B. et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther., 2, 151-163.
10. Kumagai,T. et al. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer, 121, 656-665.
11. Okamoto,H. et al. (2006) Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J. Atheroscler. Thromb., 13, 183-191.
12. Rocchi,P. et al. (2005) p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol. Rep., 13, 1139-1144.
13. Fantin,V.R. et al. (2007) Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin. Cancer Res., 13, 7237-7242.
14. Dashwood,R.H. et al. (2007) Dietary histone deacetylase inhibitors: From cells to mice to man. Semin. Cancer Biol., 17 363-369.
15. Myzak,M.C. et al. (2006) Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets, 7, 443-452.
16. Chen,C. et al. (2005) Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol. Sci., 26, 318-326.
17. Shukla,Y. et al. (2007) Cancer chemoprevention with garlic and its constituents. Cancer Lett., 247, 167-181.
18. Ross,S.A. et al. (2006) Allyl sulfur compounds from garlic modulate aberrant crypt formation. J. Nutr., 136, 852S-854S.
19. Belloir,C. et al. (2006) Protective effects of garlic sulfur compounds against DNA damage induced by direct- and indirect-acting genotoxic agents in HepG2 cells. Food Chem. Toxicol., 44, 827-834.
20. Millen,A.E. et al. (2007) Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am. J. Clin. Nutr., 86, 1754-1764.
21. Block,E. (1985) The chemistry of garlic and onions. Sci. Am., 252, 114-119.
22. Rosen,R.T. et al. (2000) The determination of metabolites of garlic preparations in breath and human plasma. Biofactors, 13 241-249.
23. Sheen,L.Y. et al. (1999) Metabolites of diallyl disulfide and diallyl sulfide in primary rat hepatocytes. Food Chem. Toxicol., 37, 1139-1146.
24. Ameen,M. et al. (2003) Garlic attenuates chrysotile-mediated pulmonary toxicity in rats by altering the phase I and phase II drug metabolizing enzyme system. J. Biochem. Mol. Toxicol., 17, 366-371.
25. Chen,C. et al. (2004) Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: Effect of chemical structure and stress signals. Free Radic. Biol. Med., 37, 1578-1590.
26. Herman-Antosiewicz,A. et al. (2004) Signal transduction pathways leading to cell cycle arrest and apoptosis induction in cancer cells by Allium vegetable-derived organosulfur compounds: A review. Mutat. Res., 555, 121-131.
27. Sambucetti,L.C. et al. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem., 274, 34940-34947.
28. Lea,M.A. et al. (2001) Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int. J. Cancer, 92, 784-789.
29. Lea,M.A. et al. (2002) Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S allylmercaptocysteine. Nutr Cancer, 43, 90-102.
30. Druesne,N. et al. (2004) Dially1 disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis, 25, 1227-1236.
31. Myzak,M.C. et al. (2004) A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res., 64, 5767-5774.
32. Myzak,M.C. et al. (2006) Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J., 20, 506-508.
33. Myzak,M.C. et al. (2006) Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis, 27, 811-819.
34. Myzak,M.C. et al. (2007) Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. (Maywood), 232, 227-234.
35. Guida,W.C. et al. (1992) Probing the conformational space available to inhibitors in the thermolysin active site using Monte Carlo/ Energy minimization techniques. J. Comput. Cheim., 13, 214-228.
36. Suzuki,T. et al. (2005) Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem., 48, 1019-1032.
37. Somoza,J.R. et al. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 12, 1325-1334.
38. Cornish-Bowden,A. (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem. J., 137, 143-144.
39. Dixon,M. (1953) The determination of enzyme inhibitor constants. Biochem. J., 55, 170-171.
40. Vannini,A. et al. (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA, 101, 15064-15069.
41. Fang,J.Y. et al. (2002) Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J. Gastroenterol., 8, 400-405.
42. Kim,Y.K. et al. (2003) Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene, 22, 6023-6031.
43. de Ruijter,A.J. et al. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 370 737-749.
44. Davis,C.D. et al. (2007) Dietary components impact histone modifications and cancer risk. Nutr. Rev., 65, 88-94.
45. Ondetti,M.A. et al. (1977) Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science, 196, 441-444.
46. Whittaker,M. et al. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 99, 2735-2776.
47. Suzuki,T. et al. (2004) Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 14 3313-3317.
48. Niculescu,A.B.III et al. (1998) Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: PRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol., 18, 629-643.
49. Iacomino,G. et al. (2006) Effects of histone deacetylase inhibitors on p55CDC/Cdc2O expression in HT29 cell line. J. Cell. Biochem., 99, 1122-1131.
50. Antosiewicz,J. et al. (2006) c-Jun NH(2)-terminal kinase signaling axis regulates diallyl trisulfide-induced generation of reactive oxygen species and cell cycle arrest in human prostate cancer cells. Cancer Res., 66, 5379-5386.
51. Xiao,D. et al. (2006) Diallyl trisulfide, a constituent of processed garlic, inactivates Akt to trigger mitochondrial translocation of BAD and caspasemediated apoptosis in human prostate cancer cells. Carcinogenesis, 27, 533-540.
52. Herman-Antosiewicz,A. et al. (2005) Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells. J. Biol. Chem., 280, 28519-28528.
53. Kobayashi,H. et al. (2004) Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Int. J. Cancer, 109, 207-213.
54. Huang,L. et al. (2000) Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene, 19, 5712-5719.
55. Ryu,H. et al. (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl Acad. Sci. USA, 100 4281-4286.
56. Ammanamanchi,S. et al. (2003) Acetylated sp3 is a transcriptional activator. J. Biol. Chem., 278, 35775-35780.
57. Xiao,H. et al. (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J. Biol. Chem., 275, 1371-1376.
58. Wilson,A.J. et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem., 281, 13548-13558.
59. Sowa,Y. et al. (1999) Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res., 59, 4266-4270.
60. Xiao,H. et al. (1999) Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem., 73, 291-302.
61. Suzuki,T. et al. (2000) Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells, 5, 29-41.
62. Huang,W. et al. (2005) Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J. Biol. Chem., 280, 10047-10054.
63. Zhao,Y. et al. (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21 (Waf1/Cip1). Mol. Cell. Biol., 26, 2782-2790.
64. RoyS. et al. (2007) Site-specific acetylation of p53 directs selective transcription complex assembly. J. Biol. Chem., 282 4765-4771.
65. Bossi,G. et al. (2007) Restoration of wild-type p53 function in human cancer: Relevance for tumor therapy. Head Neck, 29, 272-284.
66. Vikhanskaya,F. et al. (2007) Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res., 35, 2093-2104.
67. Blagosklonny,M.V. et al. (2005) Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res., 65 7386-7392.
68. Davenport,D.M. et al. (2005) Modulation of cytochrome P450 enzymes by organosulfur compounds from garlic. Food Chem. Toxicol., 43 1753-1762.
69. Walton,T.J. et al. (2008) DNA demethylation and histone deacetylation inhibition cooperate to re-express estrogen receptor beta to induce apoptosis in prostate cancer cell lines. Prostate, 68 210-222.
70. Zhu,W.G. et al. (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents, 3, 187-199.